Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis
| Autor: | Scott E. Eggener, Joseph F. Rodriguez |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Oncology medicine.medical_specialty 030232 urology & nephrology urologic and male genital diseases Sensitivity and Specificity Management of prostate cancer 03 medical and health sciences Prostate cancer 0302 clinical medicine Prostate Internal medicine medicine Humans Mass Screening Radiology Nuclear Medicine and imaging Overdiagnosis Biomarker discovery Early Detection of Cancer Mass screening business.industry Prostatic Neoplasms Cancer General Medicine Prostate-Specific Antigen medicine.disease Prostate-specific antigen medicine.anatomical_structure 030220 oncology & carcinogenesis business Biomarkers |
| Zdroj: | Radiologic Clinics of North America. 56:187-196 |
| ISSN: | 0033-8389 |
| DOI: | 10.1016/j.rcl.2017.10.002 |
| Popis: | The diagnosis and management of prostate cancer have substantially changed over the last 3 decades. Serum prostate-specific antigen (PSA) was adopted for screening in the 1990s after it was found to be a sensitive indicator of disease. Because of a lack of specificity for significant disease, indiscriminate PSA testing led to overdiagnosis and overtreatment. Several biomarkers have been developed that are superior to PSA in stratifying a man's risk for harboring potentially lethal prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|